<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371472</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Rev 2.0 (2016-09-26)</org_study_id>
    <nct_id>NCT03371472</nct_id>
  </id_info>
  <brief_title>Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of PVL.</brief_title>
  <acronym>VALE</acronym>
  <official_title>Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of Paravalvular Leak (Clinical Trial). &quot;STRATEGMED&quot; Project Integrated System for Percutaneous Closure Procedures of Paravalvular Leak.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balton Sp.zo.o.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Balton Sp.zo.o.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paravalvular leak (PVL) is a condition that could be treated surgically or by the
      transcatheter deployment of the occluder devices (plugs).

      No PVL-specific occluder device is available on the market. VALE consortium plans to design
      and validate a new PVL dedicated devices (sizing balloon and occluder) in the context of
      computer 3D modeling, bench testing, preclinical evaluation and clinical research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter closure of PVL has emerged as a new treatment strategy that can be offered to
      patients with isolated PVL or to those with a very high risk of repeat surgery. The
      transcatheter approach involves deployment of occlude devices or coils and adopting either a
      percutaneous or a transapical approach. Limitation of such approach is the fact that no
      PVL-dedicated device is available on the market, and either vascular-specific plugs or other
      types of occluders used commonly for closure of ventricular septal defects or patent ductus
      arteriosus can be used. Several technical issues can make the procedure challenging.

      The primary problem is the localization and track of the canal which can be very difficult to
      engage and cross with the guidewire. Also the maneuverability of the guide catheter in often
      enlarged left atrium and the passage of the occluder device through narrow and serpiginous
      canal between calcified annulus and sewing ring is challenging.

      Clearly the limitations of current devices and increasing number of patients with significant
      PVL warrant the attempts to design and validate new PVL-dedicated devices in the context of
      computer modeling, bench testing, preclinical evaluation and clinical translation. These
      devices, as sizing balloon, could significantly simplify and shorten the procedure, decrease
      the risk of complications and incomplete defect closure as well as optimize
      cost-effectiveness of the procedure by decreasing number of the occluders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In a group of patients with PVL there are defined two arms: one where PVL is located in mitral position (10 patients) and the second one where PVL is located in aortic position (10 patients).</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with sizing procedure success (efficacy outcome)</measure>
    <time_frame>During index procedure</time_frame>
    <description>Sizing procedure is defined as effective when all following steps: device introduction into the leakage channel, filling in the leakage channel, obtaining a balloon image in the X-ray recording and removal of the balloon without complications are performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of a combined investigational device safety endpoint (safety outcome)</measure>
    <time_frame>During index procedure</time_frame>
    <description>Safety of the investigational device defined as the occurrence/frequency of locking, fragmentation of the dimensioning balloon, enlargement of the leakage channel, locking of the mechanical prosthesis disks.
Failure to use the investigational device defined as: locking of the dimensional balloon in site, fragmentation of the dimensional balloon, enlargement of the leakage channel dimension directly related to the application of the dimensional balloon, locking of the mechanical prosthesis disks.
The failure will be assessed per investigational device and accounted for if at least one of four described events occur. Moreover, the frequency of each event will be additionally assessed and presented in per investigational device analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of major undesirable cardiovascular events</measure>
    <time_frame>30 days observation</time_frame>
    <description>MACCE defined as: cardiac and non-cardiac death, stroke, TIA, myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of hemorrhagic complications</measure>
    <time_frame>30 days observation</time_frame>
    <description>The hemorrhagic complications rated using BARC scale during 30 days follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of paravalvular leakage after procedure</measure>
    <time_frame>During index procedure</time_frame>
    <description>Evaluated in transesophageal echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the size of the paravalvular leakage channel illustrated by a dimensional balloon obtained using 3D-TEE and computerized tomography echocardiography</measure>
    <time_frame>During index procedure</time_frame>
    <description>Comparison of the measurements by sizing balloon to TEE and CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radiation dose.</measure>
    <time_frame>During index procedure</time_frame>
    <description>The amount of total radiation dose during index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total radiation time.</measure>
    <time_frame>During index procedure</time_frame>
    <description>The total radiation time of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the dimensional procedure.</measure>
    <time_frame>During index procedure</time_frame>
    <description>The duration of the dimensional procedure during index procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>PVL - Paravalvular Leak</condition>
  <arm_group>
    <arm_group_label>VALE - PVL leak sizing balloon - mitral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placement and inflation of PVL leak sizing balloon for visualisation and measurements of PVL located in mitral position - Balton developed investigational balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VALE - PVL leak sizing balloon - aortic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>'Placement and inflation of PVL leak sizing balloon for visualisation and measurements of PVL located in aortic position - Balton developed investigational balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Visualisation and measuring of paravalvular leak.</intervention_name>
    <description>Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The baloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).</description>
    <arm_group_label>VALE - PVL leak sizing balloon - mitral</arm_group_label>
    <arm_group_label>VALE - PVL leak sizing balloon - aortic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The presence of clinically and haemodynamically significant leakage around the
             surgically implanted cardiac prosthesis in the mitral or aortic position.

          -  Heart surgery (heart team) disability after another cardiac surgery.

          -  Technical feasibility of paravalvular leakage closure according to experienced
             operator.

        Exclusion Criteria:

          -  Active endocarditis on artificial valve

          -  Instability of artificial valve

          -  The amount of cavity that prevents effective closure with an occluder

          -  A history of acute coronary syndrome in less than 3 months before enrollment

          -  Confirmed echocardiography of transplatin or transesophageal echocardiography

          -  Hypersensitivity to contrast media

          -  Any condition associated with the expected life expectancy of less than 6 months

          -  Haemorrhagic diathesis

          -  Significant renal impairment (eGFR &lt;30 mL/min/1.73m2)/chronic kidney disease at &gt;G3
             stage

          -  Pregnancy or lactation

          -  Under 18 years of age

          -  Patient unable or unwilling to give an informed consent to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wojciech Wojakowski, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>III Oddział Kardiologii, Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Wojakowski, Prof.</last_name>
    <phone>+4832359 88 87</phone>
    <email>wojtek.wojakowski@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dariusz Dudek, Prof.</last_name>
    <phone>+48124247181</phone>
    <email>mcdudek@cyfronet.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>II Oddział Kliniczny Kardiologii i Interwencji Sercowo-Naczyniowych, Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <state>Małopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Dudek, Prof.</last_name>
      <phone>+4812 4247181</phone>
      <email>mcdudek@cyfronet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>III Oddział Kardiologii, Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca</name>
      <address>
        <city>Katowice</city>
        <state>Śląskie</state>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Wojakowski, Prof.</last_name>
      <phone>+4832359 88 87</phone>
      <email>wojtek.wojakowski@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Smolka G., Wojakowski W., Ochała A., Roleder T., Gąsior Z. Diagnosis and percutaneous treatment of paravalvular leaks; Post Kardiol Interw 2011; 7, 1 (23): 56-60</citation>
  </reference>
  <reference>
    <citation>Scognamiglio G, Santoro G, Fusco F, Russo MG, Sarubbi B. Percutaneous treatment of multi-valvular paraprosthetic leaks in a &quot;fragile&quot; heart. Int J Cardiol. 2016 Nov 1;222:790-791. doi: 10.1016/j.ijcard.2016.07.283. Epub 2016 Aug 2.</citation>
    <PMID>27521562</PMID>
  </reference>
  <reference>
    <citation>Murakami T, Fujii H, Sakaguchi M, Takahashi Y, Suehiro Y, Nishimura S, Sakon Y, Yasumizu D, Sohgawa E, Shibata T. Intravascular ultrasound for transcatheter paravalvular leak closure. Gen Thorac Cardiovasc Surg. 2017 Aug;65(8):466-469. doi: 10.1007/s11748-016-0700-x. Epub 2016 Aug 8.</citation>
    <PMID>27501692</PMID>
  </reference>
  <reference>
    <citation>Giacchi G, Freixa X, Hernández-Enríquez M, Sanchis L, Azqueta M, Brugaletta S, Martin-Yuste V, Masotti M, Sabaté M. Minimally Invasive Transradial Percutaneous Closure of Aortic Paravalvular Leaks: Following the Steps of Percutaneous Coronary Intervention. Can J Cardiol. 2016 Dec;32(12):1575.e17-1575.e19. doi: 10.1016/j.cjca.2016.03.013. Epub 2016 Apr 1.</citation>
    <PMID>27378589</PMID>
  </reference>
  <reference>
    <citation>Smolka G, Pysz P, Kozłowski M, Jasiński M, Gocoł R, Roleder T, Kargul A, Ochała A, Wojakowski W. Transcatheter closure of paravalvular leaks using a paravalvular leak device - a prospective Polish registry. Postepy Kardiol Interwencyjnej. 2016;12(2):128-34. doi: 10.5114/aic.2016.59363. Epub 2016 May 11.</citation>
    <PMID>27279872</PMID>
  </reference>
  <reference>
    <citation>Cruz-Gonzalez I, Rama-Merchan JC, Calvert PA, Rodríguez-Collado J, Barreiro-Pérez M, Martín-Moreiras J, Diego-Nieto A, Hildick-Smith D, Sánchez PL. Percutaneous Closure of Paravalvular Leaks: A Systematic Review. J Interv Cardiol. 2016 Aug;29(4):382-92. doi: 10.1111/joic.12295. Epub 2016 May 31. Review.</citation>
    <PMID>27242018</PMID>
  </reference>
  <reference>
    <citation>Taramasso M, Maisano F, Pozzoli A, Alfieri O, Meier B, Nietlispach F. Catheter-based treatment of paravalvular leaks. EuroIntervention. 2016 May 17;12 Suppl X:X55-X60. doi: 10.4244/EIJV12SXA11.</citation>
    <PMID>27174113</PMID>
  </reference>
  <reference>
    <citation>Hilling-Smith R, Chong A, Cox S. Mitral paravalvular leak closure by antegrade percutaneous approach using amplatzer PFO closure device. Catheter Cardiovasc Interv. 2017 Aug 1;90(2):E62-E67. doi: 10.1002/ccd.26417. Epub 2016 Apr 16.</citation>
    <PMID>27084789</PMID>
  </reference>
  <reference>
    <citation>Abdelghani M, Soliman OI, Schultz C, Vahanian A, Serruys PW. Adjudicating paravalvular leaks of transcatheter aortic valves: a critical appraisal. Eur Heart J. 2016 Sep 7;37(34):2627-44. doi: 10.1093/eurheartj/ehw115. Epub 2016 Apr 13. Review.</citation>
    <PMID>27075871</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD sharing data policy is currently restricted under grant consortium agreement and pending GDPR implementation in Europe.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

